Abstract: Disclosed are methods for treating a subject with a Complement mediated (e.g., C5a mediated) disease or an immune complex mediated disease. The method comprises the step of administering to the subject an effective amount of an agent that decreases the biological activity of iRhom2 or an agent that modulates formation of a complex between iRhom2 and TACE. Also disclosed are assays for identifying such agents.

Abstract: Described are methods for treating, preventing, or reducing the risk of, miscarriages, especially recurrent miscarriages. The methods comprise administering to a female subject a therapeutic agent that modulates the activity or binding of components of the complement system, together with a pharmaceutically acceptable carrier. For example, the therapeutic agent can be a C3-convertase inhibitor, an antibody against C5, an antagonist of the C5a receptor, or an antibody against factor B or factor D. Screening methods for agents that can prevent or reduce the risk of miscarriages, especially recurrent miscarriages, are also described.